When to treat patients with relapsed follicular lymphoma

References

• National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program populations (1969-2011) (Ed.^(Eds). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch; 2013.
   Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986;4(10):1470–1480.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13(1):140–147.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Bilgrau AE, de Nully Brown P, et al. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol. 2015;169(3):435–444.
   PubMed Web of Science ®Google Scholar
• Junlen HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 2015;29(3):668–676.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–4586.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–3301.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799–1806.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
   PubMed Web of Science ®Google Scholar
• O’Shea D, O’Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126–3129.
   PubMed Web of Science ®Google Scholar
• Koch K, Hoster E, Ziepert M, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27(7):1323–1329.
   PubMed Web of Science ®Google Scholar
• Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015;33(23):2516–2522.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Ahmed M, et al. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016;27(5):895–901.
   PubMed Web of Science ®Google Scholar
• Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol. 2014;32(13):1347–1355.
   PubMed Web of Science ®Google Scholar
• Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–181.
   PubMed Web of Science ®Google Scholar
• Bonzheim I, Salaverria I, Haake A, et al. A unique case of follicular lymphoma provides insights to the clonal evolution from follicular lymphoma in situ to manifest follicular lymphoma. Blood. 2011;118(12):3442–3444.
   PubMed Web of Science ®Google Scholar
• Mamessier E, Song JY, Eberle FC, et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica. 2014;99(3):481–488.
   PubMed Web of Science ®Google Scholar
• Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 1604-1611;121(9):2013.
   Google Scholar
• Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6(1):130–140.
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82(8):2289–2295.
   PubMed Web of Science ®Google Scholar
• Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82(7):1994–2004.
   PubMed Web of Science ®Google Scholar
• Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin’s lymphoma. Histopathology. 2002;41(4):322–330.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–2169.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Cheah CY, Gascoyne RD, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101(5):531–540.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(32):5404–5409.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a Phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 2013;5(10):1075–1087.
   PubMed Web of Science ®Google Scholar
• Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454–1459.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–522.
   PubMed Web of Science ®Google Scholar
• Kumar R, Bhargava P, Zhuang H, et al. Spontaneous regression of follicular, mantle cell, and diffuse large B-cell non-Hodgkin’s lymphomas detected by FDG-PET imaging. Clin Nucl Med. 2004;29(11):685–688.
   PubMed Web of Science ®Google Scholar
• Kato M, Uemura Y, Sato K, et al. Spontaneous remission in a patient with follicular lymphoma carrying T cell-rich neoplastic follicles and a new complex variant translocation of t(14;18): t(5;14;18)(p15;q32;q21.3). Leuk Lymphoma. 2015;56(7):2187–2189.
   PubMed Web of Science ®Google Scholar
• Young RC, Longo DL, Glatstein E, et al. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11–16.
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–1117.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–435.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014;32(28):3096–3102.
   Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National Lymphocare Study. J Clin Oncol. 2009;27(8):1202–1208.
   PubMed Web of Science ®Google Scholar
• Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of IOWA/MayoClinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol. 2013;31(26):3272–3278.
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34:2575–2582.
   PubMed Web of Science ®Google Scholar
• Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–726.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329–336.
   PubMed Web of Science ®Google Scholar
• Mac Manus MP, Rainer Bowie CA, Hoppe RT. What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma? Int J Radiat Oncol Biol Phys. 1998;42(2):365–371.
   PubMed Web of Science ®Google Scholar
• Shafey M, Lupichuk SM, Do T, et al. Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant. 2011;46(7):962–969.
   PubMed Web of Science ®Google Scholar
• Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618–3626.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl5):v83–v90.
   PubMed Web of Science ®Google Scholar
• McNamara C, Davies J, Dyer M, et al. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol. 2012;156(4):446–467.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines version 1.2015 non-Hodgkin lymphoma. Fort Washington (PA): National Comprehensive Cancer Network; 2015.
   Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Gerecitano JF, Roberts AW, Seymour JF, et al. A phase 1 study of venetoclax (ABT-199 /GDC-0199) monotherapy in patients with relapsed/Refractory non-Hodgkin lymphoma. Blood. 2015;126(23):254–254.
   Web of Science ®Google Scholar
• Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128:331–336.
   PubMed Web of Science ®Google Scholar